on VisiRose, Inc.
VisiRose Secures $3 Million Seed Funding to Advance Ocular Therapies
VisiRose Inc., a Knoxville-based biotechnology company, has raised $3 million in a seed financing round. The funding will advance VisiRose's leading investigational program targeting corneal diseases and other severe ocular conditions.
The investment will support key initiatives, including a pre-investigational new drug meeting with the FDA for its Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a treatment for eye infections. VisiRose will also submit an IND application for PV-305, aimed at addressing corneal blindness through photodynamic therapy.
VisiRose is collaborating with the University of Miami's Bascom Palmer Eye Institute and Provectus Biopharmaceuticals to develop these therapies using Rose Bengal Sodium. CEO Dominic Rodrigues expressed optimism about advancing the drug pipeline.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VisiRose, Inc. news